- Home
- AMPL vs ATAI Comparison
AMPL vs ATAI Comparison
Compare AMPL & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMPL
- ATAI
- Stock Information
- Founded
- AMPL 2012
- ATAI 2018
- Country
- AMPL United States
- ATAI Netherlands
- Employees
- AMPL N/A
- ATAI N/A
- Industry
- AMPL EDP Services
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- AMPL Technology
- ATAI Health Care
- Exchange
- AMPL Nasdaq
- ATAI Nasdaq
- Market Cap
- AMPL 1.7B
- ATAI 1.6B
- IPO Year
- AMPL 2021
- ATAI 2021
- Fundamental
- Price
- AMPL $11.10
- ATAI $4.39
- Analyst Decision
- AMPL Buy
- ATAI Strong Buy
- Analyst Count
- AMPL 11
- ATAI 5
- Target Price
- AMPL $14.45
- ATAI $14.00
- AVG Volume (30 Days)
- AMPL 1.8M
- ATAI 7.1M
- Earning Date
- AMPL 11-05-2025
- ATAI 11-12-2025
- Dividend Yield
- AMPL N/A
- ATAI N/A
- EPS Growth
- AMPL N/A
- ATAI N/A
- EPS
- AMPL N/A
- ATAI N/A
- Revenue
- AMPL $329,919,000.00
- ATAI $2,309,000.00
- Revenue This Year
- AMPL $15.04
- ATAI $736.04
- Revenue Next Year
- AMPL $12.93
- ATAI N/A
- P/E Ratio
- AMPL N/A
- ATAI N/A
- Revenue Growth
- AMPL 12.78
- ATAI 510.85
- 52 Week Low
- AMPL $7.55
- ATAI $1.15
- 52 Week High
- AMPL $14.88
- ATAI $6.75
- Technical
- Relative Strength Index (RSI)
- AMPL 62.63
- ATAI 35.03
- Support Level
- AMPL $9.64
- ATAI $4.14
- Resistance Level
- AMPL $10.24
- ATAI $4.65
- Average True Range (ATR)
- AMPL 0.47
- ATAI 0.35
- MACD
- AMPL 0.19
- ATAI -0.19
- Stochastic Oscillator
- AMPL 83.41
- ATAI 9.81
About AMPL Amplitude Inc.
Amplitude Inc is a Software company that provides a Digital Analytics Platform that helps companies analyze their customer behavior within digital products. The Company delivers its application over the Internet as a subscription service using a software-as-a-service (SaaS) model and also it offers customer support related to initial implementation setup, ongoing support services, and application training. The company generates revenue primarily through selling subscriptions to the platform. The company derives a majority of its revenue from the United States.
About ATAI ATAI Life Sciences N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.